Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide and Surfactant to Prevent BPD in VLBW Infants
NCT03275415Phase 4Completed
- Sponsor
- Taipei Medical University
- Start
- Jul 2019
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of budesonide in bronchopulmonary dysplasia (BPD), sponsored by Taipei Medical University. Primary endpoint: Incidence of death or bronchopulmonary dysplasia at 6 months. Started Jul 2019; status: completed.
02
Drugs
budesonide
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT03275415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03275415.